Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Membrane Hsp70-supported cell-to-cell connections via tunneling nanotubes revealed by live-cell STED nanoscopy.

Reindl J, Shevtsov M, Dollinger G, Stangl S, Multhoff G.

Cell Stress Chaperones. 2019 Jan 10. doi: 10.1007/s12192-018-00958-w. [Epub ahead of print]

PMID:
30632067
2.

Membrane Hsp70-A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition.

Breuninger S, Stangl S, Werner C, Sievert W, Lobinger D, Foulds GA, Wagner S, Pickhard A, Piontek G, Kokowski K, Pockley AG, Multhoff G.

Front Oncol. 2018 Nov 1;8:497. doi: 10.3389/fonc.2018.00497. eCollection 2018.

3.

Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging.

Stangl S, Tei L, De Rose F, Reder S, Martinelli J, Sievert W, Shevtsov M, Öllinger R, Rad R, Schwaiger M, D'Alessandria C, Multhoff G.

Cancer Res. 2018 Nov 1;78(21):6268-6281. doi: 10.1158/0008-5472.CAN-18-0707. Epub 2018 Sep 18.

PMID:
30228173
4.

Molecular AFM imaging of Hsp70-1A association with dipalmitoyl phosphatidylserine reveals membrane blebbing in the presence of cholesterol.

Lamprecht C, Gehrmann M, Madl J, Römer W, Multhoff G, Ebner A.

Cell Stress Chaperones. 2018 Jul;23(4):673-683. doi: 10.1007/s12192-018-0879-0. Epub 2018 Feb 5.

5.

Membrane heat shock protein 70: a theranostic target for cancer therapy.

Shevtsov M, Huile G, Multhoff G.

Philos Trans R Soc Lond B Biol Sci. 2018 Jan 19;373(1738). pii: 20160526. doi: 10.1098/rstb.2016.0526. Review.

6.

Immunohistochemical and Flow Cytometric Analysis of Intracellular and Membrane-Bound Hsp70, as a Putative Biomarker of Glioblastoma Multiforme, Using the cmHsp70.1 Monoclonal Antibody.

Stangl S, Foulds GA, Fellinger H, Pilkington GJ, Pockley AG, Multhoff G.

Methods Mol Biol. 2018;1709:307-320. doi: 10.1007/978-1-4939-7477-1_22.

PMID:
29177668
7.

Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models.

Friedrich L, Kornberger P, Mendler CT, Multhoff G, Schwaiger M, Skerra A.

Biol Chem. 2018 Feb 23;399(3):235-252. doi: 10.1515/hsz-2017-0207.

PMID:
29140786
8.

Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.

Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G.

Front Immunol. 2017 Oct 18;8:1305. doi: 10.3389/fimmu.2017.01305. eCollection 2017.

9.

Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.

Thorsteinsdottir J, Stangl S, Fu P, Guo K, Albrecht V, Eigenbrod S, Erl J, Gehrmann M, Tonn JC, Multhoff G, Schichor C.

J Neurooncol. 2017 Dec;135(3):443-452. doi: 10.1007/s11060-017-2600-z. Epub 2017 Aug 28.

PMID:
28849427
10.

Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer.

Shevtsov M, Multhoff G.

Front Immunol. 2016 Apr 29;7:171. doi: 10.3389/fimmu.2016.00171. eCollection 2016. Review.

11.

Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 monoclonal antibodies (SPION-cmHsp70.1).

Shevtsov MA, Nikolaev BP, Ryzhov VA, Yakovleva LY, Marchenko YY, Parr MA, Rolich VI, Mikhrina AL, Dobrodumov AV, Pitkin E, Multhoff G.

Nanoscale. 2015 Dec 28;7(48):20652-64. doi: 10.1039/c5nr06521f. Epub 2015 Nov 24.

PMID:
26599206
12.

Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer.

Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G.

Front Immunol. 2015 Nov 2;6:556. doi: 10.3389/fimmu.2015.00556. eCollection 2015.

13.

Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles.

Gehrmann MK, Kimm MA, Stangl S, Schmid TE, Noël PB, Rummeny EJ, Multhoff G.

Int J Nanomedicine. 2015 Sep 8;10:5687-700. doi: 10.2147/IJN.S87174. eCollection 2015.

14.

Role of membrane Hsp70 in radiation sensitivity of tumor cells.

Murakami N, Kühnel A, Schmid TE, Ilicic K, Stangl S, Braun IS, Gehrmann M, Molls M, Itami J, Multhoff G.

Radiat Oncol. 2015 Jul 22;10:149. doi: 10.1186/s13014-015-0461-1.

15.

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.

Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G.

Front Immunol. 2015 Apr 15;6:162. doi: 10.3389/fimmu.2015.00162. eCollection 2015. Review.

16.

The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation.

Multhoff G, Pockley AG, Schmid TE, Schilling D.

Cancer Lett. 2015 Nov 28;368(2):179-84. doi: 10.1016/j.canlet.2015.02.013. Epub 2015 Feb 11. Review.

17.

Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe.

Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G.

Cancer Res. 2014 Dec 1;74(23):6903-12. doi: 10.1158/0008-5472.CAN-14-0413. Epub 2014 Oct 9.

18.

Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide.

Gehrmann M, Stangl S, Foulds GA, Oellinger R, Breuninger S, Rad R, Pockley AG, Multhoff G.

PLoS One. 2014 Aug 28;9(8):e105344. doi: 10.1371/journal.pone.0105344. eCollection 2014.

19.

A hypoxia-induced decrease of either MICA/B or Hsp70 on the membrane of tumor cells mediates immune escape from NK cells.

Schilling D, Tetzlaff F, Konrad S, Li W, Multhoff G.

Cell Stress Chaperones. 2015 Jan;20(1):139-47. doi: 10.1007/s12192-014-0532-5. Epub 2014 Aug 8.

20.

Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, Specht HM, Multhoff G.

Front Immunol. 2014 Jul 1;5:307. doi: 10.3389/fimmu.2014.00307. eCollection 2014.

Supplemental Content

Loading ...
Support Center